In a dramatic turn for one of Colorado’s high-profile healthcare companies, a federal judge has preliminarily approved a $27 million settlement between InnovAge Holding Corp., its IPO underwriters, and a class of investors who allege they were misled by the company’s 2021 stock debut — only to watch their investments unravel after a government crackdown exposed deep flaws.

U.S. District Judge William J. Martinez signed off on the tentative agreement Tuesday, greenlighting a deal that marks the culmination of three years of litigation and a searing lesson in the risks of public market hype amid regulatory blind spots.

The IPO That Soared—Then Crashed

When InnovAge launched its initial public offering in March 2021, shares opened at $21 and soared to nearly $26 in a matter of days. But the honeymoon ended abruptly when a Centers for Medicare & Medicaid Services (CMS) audit led to the closure of an InnovAge center in California.

CMS investigators concluded the facility had "substantially failed" to deliver services required under PACE — the Program of All-Inclusive Care for the Elderly. The news sparked a stock price free fall, plunging from $14 to $6.76, according to court documents.

Then came another blow: InnovAge revealed that all Colorado-based centers — representing more than half of its total revenue — had their enrollments suspended by both CMS and state regulators over similar patient care issues, many allegedly predating the IPO.

The share price collapsed further, ultimately representing a 78% decline from the IPO’s peak — devastation for investors who claimed they were never warned of such risks.

Shareholders Strike Back

Led by the El Paso Firemen & Policemen's Pension Fund, San Antonio Fire & Police Pension Fund, and the Indiana Public Retirement System, the plaintiffs argued that InnovAge’s IPO materials omitted material risks and painted an overly rosy picture of compliance and operations.

The lawsuit also targeted underwriters like J.P. Morgan Securities LLC and Barclays Capital Inc., accusing them of failing to adequately flag operational red flags during the IPO process.

In their motion for approval, plaintiffs' attorneys said the $27 million deal represents a “substantial percentage of the maximum realistically recoverable damages,” and emphasized the value of securing immediate relief versus rolling the dice on extended trial proceedings.

Legal Teams at the Helm

The plaintiffs are represented by a powerhouse team from Cohen Milstein Sellers & Toll PLLC, including Julie G. Reiser, Molly Bowen, and others, alongside Fairfield & Woods PC. The legal team has requested up to 20% of the settlement in fees, plus $800,000 in expenses.

The underwriters are defended by a Freshfields LLP team led by Mary Eaton, Nicholas A. Caselli, and Abhinaya Swaminathan.

A Pricey Lesson in Disclosure and Due Diligence

Though the settlement is not an admission of wrongdoing, it sends a sharp message about the perils of cutting corners in disclosure and the enduring reach of federal watchdogs. InnovAge may have sold a vision of accessible senior care at scale — but investors were ultimately left holding the bill when regulatory reality collided with Wall Street optimism.

The court’s final approval hearing is expected later this year, where the deal could be cemented — and a bruised investor class may finally see restitution.